Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Raetz

Showing results (51-60 of 155) with videos related to

Pageof 16
Sort By:
Blood Advances|October 25, 2024
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 studyLuke Maese, Mignon L Loh, Mi Rim Choi, et al.
British Journal of Haematology|July 20, 2016
Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemiaRachel E Rau, Andrew J Carroll, Nyla A Heerema, et al.
Blood|July 11, 2006
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group studyDeepa Bhojwani, Huining Kang, Naomi P Moskowitz, et al.
Cancer|November 8, 2017
Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trialDaniel J Zheng, Xiaomin Lu, Reuven J Schore, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
The Journal of Biological Chemistry|June 5, 2014
Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia modelCourtney L Jones, Teena Bhatla, Roy Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology GroupKristina K Hardy, Leanne Embry, John A Kairalla, et al.
Haematologica|April 21, 2019
Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology GroupElizabeth A Raetz, Mignon L Loh, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2017
Reply to I.J. CohenKristina K Hardy, Leanne M Embry, John A Kairalla, et al.
Pageof 16

Showing results (51-60 of 155) with videos related to

Sort By:
Pageof 16
Blood Advances|October 25, 2024
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children's Oncology Group AALL1931 studyLuke Maese, Mignon L Loh, Mi Rim Choi, et al.
British Journal of Haematology|July 20, 2016
Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemiaRachel E Rau, Andrew J Carroll, Nyla A Heerema, et al.
Blood|July 11, 2006
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group studyDeepa Bhojwani, Huining Kang, Naomi P Moskowitz, et al.
Cancer|November 8, 2017
Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trialDaniel J Zheng, Xiaomin Lu, Reuven J Schore, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
The Journal of Biological Chemistry|June 5, 2014
Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia modelCourtney L Jones, Teena Bhatla, Roy Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2017
Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology GroupKristina K Hardy, Leanne Embry, John A Kairalla, et al.
Haematologica|April 21, 2019
Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology GroupElizabeth A Raetz, Mignon L Loh, Meenakshi Devidas, et al.
Pediatric Blood & Cancer|June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2017
Reply to I.J. CohenKristina K Hardy, Leanne M Embry, John A Kairalla, et al.
Pageof 16